The Why Behind Our Work
We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. Our novel mRNA and gene correction therapeutics have the potential to make this a reality.
Our Story Begins with Unconventional Thinking
For years, LNP delivery was confined to the liver and vaccines, limiting the reach of genetic medicines. The discovery that adding one or two lipids with specific characteristics enables LNPs to withstand nebulization and target specific cells opened the possibility of treating genetic diseases of the lung. This breakthrough led to the development of our proprietary Inhaled LNP Delivery Platform and was further extended to the Targeted LNP Delivery Platform, which powers ReCode’s pipeline of genetic medicines.
We are pioneering disease-modifying mRNA and gene correction therapeutics for genetically defined diseases with few or no current treatment options.
Our lead programs are focused on cystic fibrosis.
We are pioneering disease-modifying mRNA and gene correction therapeutics for genetically defined diseases with few or no current treatment options.
Our lead programs are focused on primary ciliary dyskinesia and cystic fibrosis.
Therapeutic Areas of Focus
Cystic Fibrosis (CF)
Using our proven inhaled LNP platform, we are tackling CF from multiple angles, including mRNA therapy and gene correction, to treat the disease’s underlying cause so more people with CF may benefit.
